The essentials of locoregional control in the treatment of gastric cancer

Scandinavian Journal of Surgery

Volumn 95, Issue 4, 2006, Pages 236-242

  Den Dulk, M ^a   Verheij, M ^b   Cats, A ^b   Jansen, E P M ^b   Hartgrink, H H ^a   Van De Velde, Cornelis J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

(Neo)adjuvant treatment; Gastric cancer; Local recurrence; Lymph node dissection; Quality assurance; Randomised trials

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE;

CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER INHIBITION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; HUMAN; LYMPH NODE DISSECTION; POSTOPERATIVE CARE; QUALITATIVE ANALYSIS; REVIEW; STOMACH CANCER; SURGICAL MORTALITY; TREATMENT OUTCOME;

EID: 33846124574     PISSN: 14574969     EISSN: None     Source Type: Journal    
DOI: 10.1177/145749690609500405     Document Type: Review

References (58)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-543
2. Akoh JA, Macintyre IM: Improving survival in gastric cancer: review of 5-year survival rates in English language publications from 1970. Br J Surg 1992;79:293-299
3. Hisamichi S, Sugawara N: Mass screening for gastric cancer by X-ray examination. Jpn J Clin Oncol 1984;14:211-223
4. Fujii M, Sasaki J, Nakajima T: State of the art in the treatment of gastric cancer: from the 71st Japanese Gastric Cancer Congress. Gastric Cancer 1999;2:151-157
5. Sasako M, Sano T, Yamamoto S, Nashimoto A, Kurita A, Furukawa H, Tsujinaka T, Kinoshita T, Arai K, Japan Clinical Oncology Group: Randomized phase III trial of standard D2 versus D2 + para-aortic lymph node (PAN) dissection (D) for clinically MO advanced gastric cancer: JCOG9501. J Clin Oncol (Meeting Abstracts) 2006;24:LBA4015
6. Kajitani T: The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg 1981;11:127-139
7. Baba H, Maehara Y, Takeuchi H, Inutsuka S, Okuyama T, Adachi Y, Akazawa K, Sugimachi K: Effect of lymph node dissection on the prognosis in patients with node-negative early gastric cancer. Surgery 1995;117:165-169
8. Pacelli F, Doglietto GB, Bellantone R, Alfieri S, Sgadari A, Crucitti F: Extensive versus limited lymph node dissection for gastric cancer: a comparative study of 320 patients. Br J Surg 1993;80:1153-1156
9. McArdle CS, Hole D: Impact of variability among surgeons on postoperative morbidity and mortality and ultimate survival. BMJ 1991;302:1501-1505
10. Peeters KC, van de Velde CJH: Surgical quality assurance in rectal cancer treatment: the key to improved outcome. Eur J Surg Oncol 2005;31:630-635
11. Belletti S, Dutreix A, Garavaglia G, Gfirtner H, Haywood J, Jessen KA, Lamm IL, Mijnheer B, Noel A, Nusslin F, Rosenow U, Schneider P, Seelentag W, Sheriff S, Svensson H, Thwaites D: Quality assurance in radiotherapy: the importance of medical physics staffing levels. Recommendations from an ESTRO/EFOMP joint task group. Radiother Oncol 1996;41:89-94
12. Bentzen SM, Bernier J, Davis JB, Horiot JC, Garavaglia G, Chavaudra J, Johansson KA, Bolla M: Clinical impact of dosimetry quality assurance programmes assessed by radiobiological modelling of data from the thermoluminescent dosimetry study of the European Organization for Research and Treatment of Cancer. Eur J Cancer 2000;36:615-620
13. Kehoe T, Rugg LJ: From technical quality assurance of radiotherapy to a comprehensive quality of service management system. Radiother Oncol 1999;51:281-290
14. Leer JW, Corver R, Kraus JJ, vd Togt JC, Buruma OJ: A quality assurance system based on ISO standards: experience in a radiotherapy department. Radiother Oncol 1995;35:75-81
15. Thwaites D, Scalliet F, Leer JW, Overgaard J: Quality assurance in radiotherapy. European Society for Therapeutic Radiology and Oncology Advisory Report to the Commission of the European Union for the 'Europe Against Cancer' Programme. Radiother Oncol 1995;35:61-73
16. Thwaites D: Quality assurance into the next century. Radiother Oncol 2000;54:vii-vix
17. Favalli G, Vermorken JB, Vantongelen K, Renard J, Van Oosterom AT, Pecorelli S: Quality control in multicentric clinical trials. An experience of the EORTC Gynecological Cancer Cooperative Group. Eur J Cancer 2000;36:1125-1133
18. Vantongelen K, Steward W, Blackledge G, Verweij J, Van Oosterom A: EORTC joint ventures in quality control: treatment-related variables and data acquisition in chemotherapy trials. Eur J Cancer 1991;27:201-207
19. Verweij J, Nielsen OS, Therasse P, Van Oosterom AT: The use of a systemic therapy checklist improves the quality of data acquisition and recording in multicentre trials. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1997;33:1045-1049
20. MacFarlane JK: Nodal metastases in rectal cancer: the role of surgery in outcome. Surg Oncol Clin N Am 1996;5:191-202
21. Heald RJ, Ryall RD: Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986;327:1479-1482
22. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730
23. Martling AL, Holm T, Rutqvist LE, Moran BJ, Heald RJ, Cedemark B: Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet 2000;356:93-96
24. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, Kjaer M, Gadeberg CC, Mouridsen HT, Jensen MB, Zedeler K: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949-955
25. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJH: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-646
26. Kapiteijn E, Marijnen CA, Colenbrander AC, Klein Kranenbarg E, Steup WH, van Krieken JH, van Houwelingen JC, Leer JW, van de Velde CJH: Local recurrence in patients with rectal cancer diagnosed between 1988 and 1992: a population-based study in the west Netherlands. Eur J Surg Oncol 1998;24:528-535
27. van den Brink M, Stiggelbout AM, van den Hout WB, Kievit J, Klein Kranenbarg E, Marijnen CA, Nagtegaal ID, Rutten HJ, Wiggers T, van de Velde CJH: Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy. J Clin Oncol 2004;22:3958-3964
28. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJH, Welvaart K, Songun I, Meyer S, Plukker JTM, van Elk P, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H: Extended lymph-node dissection for gastric cancer. N Engl J Med 1999;340:908-914
29. Bunt AM, Hermans J, Boon MC, van de Velde CJH, Sasako M, Fleuren GJ, Bruijn JA: Evaluation of the extent of lymphadenectomy in a randomized trial of Western- versus Japanese-type surgery in gastric cancer. J Clin Oncol 1994;12:417-122
30. Hartgrink HH, van de Velde CJH, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, Welvaart K, van Krieken JH, Meijer S, Plukker JTM, van Elk PJ, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H, Sasako M: Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004;22:2069-2077
31. Putter H, Sasako M, Hartgrink HH, van de Velde CJH, van Houwelingen JC: Long-term survival with non-proportional hazards: results from the Dutch Gastric Cancer Trial. Stat Med 2005;24:2807-2821
32. Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JTM, van Elk P, Obertop H, Gouma DJ, Taat CW, van Lanschot J, Meyer S, de Graaf PW, von Meyenfeldt MF, Tilanus H, van de Velde CJH: Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995;345:745-748
33. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P: Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999;79:1522-1530
34. McCulloch P, Niita ME, Kazi H, Gama-Rodrigues JJ: Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer. Br J Surg 2005;92:5-13
35. Yu W, Choi GS, Chung HY: Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006;93:559-563
36. Petrelli NJ: The debate is over; it's time to move on. J Clin Oncol 2004;22:2041-2042
37. van de Velde CJH, Peeters KC: The gastric cancer treatment controversy. J Clin Oncol 2003;21:2234-2236
38. Nakajima T: Gastric cancer treatment guidelines in Japan. Gastric Cancer 2002;5:1-5
39. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, Lui WY, Whang-Peng J: Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006;7: 309-315
40. Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono H, Nagahori Y, Hosoi H, Takahashi M, Kito F, Shimada H: Comparison of surgical results of D2 versus D3 gastrectomy (para-aortic lymph node dissection) for advanced gastric carcinoma: a multi-institutional study. Ann Surg Oncol 2006;13: 659-667
41. Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999;35:1059-1064
42. Gianni L, Panzini I, Tassinari D, Mianulli AM, Desiderio F, Ravaioli A: Meta-analyses of randomized trials of adjuvant chemotherapy in gastric cancer. Ann Oncol 2001;12:1178-1180
43. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, van de Velde CJH: Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993;11:1441-1447
44. Janunger KG, Hafstrom L, Glimelius B: Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 2002;168:597-608
45. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, Cascinu S, Barni S, Labianca R, Torri V: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparate Digerente). Ann Oncol 2000;11:837-843
46. Hartgrink HH, van de Velde CJH, Putter H, Songun I, Tesselaar ME, Klein Kranenbarg E, de Vries JE, Wils JA, van der Bijl J, van Krieken JH: Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004;30:643-649
47. Cunningham D, Allum WH, Stenning SP, Thompson JN, van de Velde CJH, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20
48. Hallissey MT, Dunn JA, Ward LC, Allum WH: The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 1994;343:1309-1312
49. Jansen EPM, Boot H, Verheij M, van de Velde CJH: Optimal locoregional treatment in gastric cancer. J Clin Oncol 2005;23: 4509-4517
50. Kim S, Lim DH, Lee J, Kang WK, Macdonald JS, Park CH, Park SH, Lee SH, Kim K, Park JO, Kim WS, Jung CW, Park YS, Im YH, Sohn TS, Noh JH, Heo JS, Kim YI, Park CK, Park K: An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005;63:1279-1285
51. Kampschoer GH, Maruyama K, van de Velde CJ, Sasako M, Kinoshita T, Okabayashi K: Computer analysis in making preoperative decisions: a rational approach to lymph node dissection in gastric cancer patients. Br J Surg 1989;76:905-908
52. Bollschweiler E, Boettcher K, Hoelscher AH, Sasako M, Kinoshita T, Maruyama K, Siewert JR: Preoperative assessment of lymph node metastases in patients with gastric cancer: evaluation of the Maruyama computer program. Br J Surg 1992;79:156-160
53. Guadagni S, de Manzoni G, Catarci M, Valenti M, Amicucci G, De Bernardinis G, Cordiano C, Carboni M, Maruyama K: Evaluation of the Maruyama computer program accuracy for preoperative estimation of lymph node metastases from gastric cancer. World J Surg 2000;24:1550-1558
54. Peeters KC, Hundahl SA, Klein Kranenbarg E, Hartgrink HH, van de Velde CJH: Low Maruyama index surgery for gastric cancer: blinded reanalysis of the Dutch D1-D2 trial. World J Surg 2005;29:1576-1584
55. Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T: Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol 2002;9:278-286
56. Jansen EPM, Saunders MP, Boot H, Oppedijk V, Dubbelman R, Porritt B, Cats A, Stroom J, Valdés Olmos R, Bartelink H, Verheij M: A prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys 2006 (in Press)
57. Ringash J, Perkins G, Brierley J, Lockwood G, Islam M, Catton P, Cummings B, Kim J, Wong R, Dawson L: IMRT for adjuvant radiation in gastric cancer: a preferred plan? Int J Radiat Oncol Biol Phys 2005;63:732-738
58. Verheij M, Oppedijk V, Boot H, Cats A, Saunders M, Khoo V, Valdes Olmos R, Dubbelman R, Bartelink H, Jansen EPM: Late renal toxicity following post-operative chemoradiotherapy in gastric cancer. ASCO 2005 Gastrointestinal Cancers Symposium, Esophagus and Stomach, Multidisciplinary Treatment 2005; Abstract No.2